Apr 17, 2009 - Sepracor Inc. (Nasdaq: SEPR) today announced that the Board of Patent Appeals and Interferences (BPAI) of the U.S. Patent and Trademark Office has combined three patent interferences into a single interference between Sepracor and Wyeth and set a date for oral arguments. The interference seeks to determine the priority of inventorship of claims directed to racemic O-desmethylvenlafaxine (ODMV) succinate.
The details can be read here.
No comments:
Post a Comment